Navigation Links
Date Set for LightLab Damages Trial Against Volcano and Axsun
Date:2/9/2010

WESTFORD, Mass., Feb. 9 /PRNewswire/ -- LightLab Imaging, Inc., pioneer and leader in the development of Optical Coherence Tomography (OCT) for coronary artery applications, today reported that Trial Judge Margaret Hinkle has set March 22 for the commencement of the next phase of an ongoing trial to address damages LightLab Imaging is claiming against Volcano Corporation and its wholly owned subsidiary, Axsun Technologies, Inc.  After a four week trial that addressed only the liability claims in this litigation, a 13 person jury in the Massachusetts Superior Court rendered its liability verdict on February 4, 2010, finding:  

  • Axsun, which was acquired by Volcano in December 2008, breached its exclusive contract with LightLab Imaging
  • Axsun and Volcano misappropriated LightLab's trade secret information
  • Volcano was unjustly enriched by gaining access to LightLab's trade secret information
  • Volcano intentionally interfered both with LightLab's contract and with LightLab's advantageous business relationship with Axsun
  • Axsun breached the implied covenant of good faith and fair dealing in the LightLab contract

In addition, the jury found for LightLab in a dispute over the interpretation of LightLab's rights of exclusivity under its contract with Axsun, and found for LightLab that the contract had been modified to require Axsun to deliver a particular state-of-the-art laser to LightLab.

At a future date, LightLab will also be asking the Court to issue injunctions against Volcano and Axsun consistent with the jury's findings.  

About LightLab Imaging

LightLab Imaging, Inc., based in Westford, MA is the world's leading manufacturer and marketer of Optical Coherence Tomography (OCT) for vascular and other imaging applications. LightLab currently sells its OCT systems and imaging catheters in twenty countries in Europe, Asia, the Middle East and South America. It currently does not sell products in the United States for clinical use. The company was founded in 1998 by the inventors of OCT, and has exclusive license to a broad range of OCT technologies and applications from MIT and other entities. The LightLab mission is to develop and distribute photonic imaging technologies that improve patient's wellbeing, enhance diagnostic medicine, improve outcomes, and reduce healthcare expenditures. With the ability to resolve real-time images to 15 micrometers, the LightLab Imaging OCT Imaging Systems offer physicians more information, and more precise information, than ever before available. For more information, visit www.lightlabimaging.com.

SOURCE LightLab Imaging, Inc.

RELATED LINKS
http://www.lightlabimaging.com

'/>"/>

SOURCE LightLab Imaging, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
2. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
3. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
4. Centerphase Solutions, Inc. Launches New Clinical Trials Business Model Company
5. Delcath Systems Begins Data Analysis of Phase III Trial
6. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
7. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
8. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
9. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
10. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
11. Pivotal Trial Results for Motavizumab Published in Current Issue of Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... First Choice Emergency Room ... Dr. Douglas J. Harrison, as the new Medical Director of its Sienna Plantation facility. ... Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, Area Medical ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... With low back pain afflicting 8 of ... what causes its kissing cousin – upper back pain. But this equally vexing condition stems ... options, according to Kaixuan Liu, MD, PhD , founder and president of Atlantic Spine ...
(Date:8/15/2017)... ... August 15, 2017 , ... Medicine is much more than ... who feels isolated. It’s developing relationships and thereby growing the mind. It’s finding ... MD, PhD, invited three renowned authors and academic leaders – and decades-long friends ...
(Date:8/15/2017)... ... 2017 , ... The Philadelphia Marathon and the American Association for Cancer Research ... the City’s commitment to improving the health of its citizens. Dedicated to preventing and ... healthy lifestyle as research shows this can help reduce the risk of cancer. ...
(Date:8/15/2017)... ... August 15, 2017 , ... The V Foundation for Cancer ... V Foundation Wine Celebration raised nearly $9 million for cancer research during a ... “Fund-A-Need” donations to support the study of BRCA mutation research in laboratories and ...
Breaking Medicine News(10 mins):